Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Kiran NaqviElias J JabbourJeffrey SkinnerKristin AndersonSara DellasalaMusa YilmazAlessandra FerrajoliPrithviraj BosePhilip ThompsonYesid AlvaradoNitin JainKoichi TakahashiJan BurgerZeev EstrovGautam BorthakurNaveen PemmarajuShilpa PaulJorge CortesHagop M KantarjianPublished in: Cancer (2019)
These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for early CML-CP.